Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis
Official journal of the American College of Gastroenterology| ACG, 2004•journals.lww.com
BACKGROUND: Tumor necrosis factor-α (TNF-α) has been incriminated to play an important
role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Pentoxifylline, a TNF-α
inhibitor could prove useful in treating patients with NASH. METHODS: Eighteen patients
(mean age, 34±7.8 yr) with histologically proven NASH and with persistently elevated ALT (>
1.5 times) were given pentoxifylline at a dosage of 400 mg tid for 6 months. No lipid-lowering
agent or antioxidants were concurrently advised. RESULTS: Impaired fasting glycemia …
role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Pentoxifylline, a TNF-α
inhibitor could prove useful in treating patients with NASH. METHODS: Eighteen patients
(mean age, 34±7.8 yr) with histologically proven NASH and with persistently elevated ALT (>
1.5 times) were given pentoxifylline at a dosage of 400 mg tid for 6 months. No lipid-lowering
agent or antioxidants were concurrently advised. RESULTS: Impaired fasting glycemia …
Abstract
BACKGROUND:
Tumor necrosis factor-α (TNF-α) has been incriminated to play an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Pentoxifylline, a TNF-α inhibitor could prove useful in treating patients with NASH.
METHODS:
Eighteen patients (mean age, 34±7.8 yr) with histologically proven NASH and with persistently elevated ALT (> 1.5 times) were given pentoxifylline at a dosage of 400 mg tid for 6 months. No lipid-lowering agent or antioxidants were concurrently advised.
RESULTS:
Impaired fasting glycemia, impaired glucose tolerance, diabetes mellitus, and hypertriglyceridemia were noted in 6, 35, 17, and 53% of the patients, respectively.
Lippincott Williams & Wilkins以上显示的是最相近的搜索结果。 查看全部搜索结果